Dyskinesias in Parkinson's Disease, Preclinical Modeling and Therapeutic Alternatives

Abstract

Introduction: Dyskinesia represents the most common motor complication of levodopa pharmacotherapy. Most patients with Parkinson's disease tend to develop dyskinesias, hence the evaluation of new therapeutic alternatives capable of reducing, eliminating or avoiding their occurrence is a necessity.

Objective: To address dyskinesias associated with Parkinson's disease, their clinical presentation and pathophysiology, as well as therapeutic alternatives and preclinical modeling.

Methods: Bibliographic review, in a scientific database, of articles related to the topic and published between 1991 and 2022. 120 articles were found, 47 were included after meeting the selection, scientific relevance and methodological criteria.

Conclusions: Although dyskinesia is a well-known complication of chronic levodopa therapy, options for its medical treatment are limited and often challenging.